Catalyst
Slingshot members are tracking this event:
Advisory Committee Meeting on October 12, 2017 for Spark Therapeutics (ONCE) Voretigene neparvovec (SPK-RPE65) in treating vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ONCE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 12, 2017
Occurred Source:
http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2306441
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda Ad-comm, Voretigene Neparvovec, Spk-rpe65, Vision Loss, Biallelic Rpe65 Mutation, Retinal Dystrophy
